MO

Marc Odrich

Chief Medical Officer

LENZ Therapeutics

LENZ Therapeutics Pipeline

DrugIndicationPhase
VIZZ™ (aceclidine ophthalmic solution) 1.44%PresbyopiaApproved
LNZ101 (aceclidine/brimonidine)PresbyopiaPhase 3